Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-toxigenic Clostridioides difficile colonization in healthy volunteers
NL-OMON56374Completed
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2023
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of nontoxigenic Clostridioides difficile strain M3 and vancomycin in Clostridioides difficile colitis (CDI) (4 arms), sponsored by Leiden University Medical Center. Primary endpoints: Adverse events during first month after NTCD ingestion and Successful colonization with NTCD. Started Sep 2023; status: completed.
02
Drugs
nontoxigenic Clostridioides difficile strain M3vancomycin
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on NL-OMON56374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56374.